Gilead's Sunlenca Shows 100% Efficacy in HIV Prevention Trial

Jun 20, 2024, 12:54 PM

Gilead Sciences announced that its twice-yearly injectable antiviral drug, lenacapavir, also known as Sunlenca, demonstrated 100% efficacy in preventing HIV infection in women during a late-stage trial. The study, which included over 2,000 women, showed that lenacapavir was more effective than the company's existing daily pill, Truvada. Researcher Joe Eron described the results as remarkable, noting that there were no infections among the participants. This trial is part of Gilead's most comprehensive and diverse HIV prevention program to date, underscoring the company's commitment to serving the needs of individuals seeking pre-exposure prophylaxis (PrEP).